Αρχειοθήκη ιστολογίου

Κυριακή 7 Απριλίου 2019

Clinical Trials

A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403
Retrospective studies have suggested that older adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) have better survival rates when treated using a pediatric ALL regimen administered by pediatric treatment teams. To address the feasibility and efficacy of using a pediatric treatment regimen for AYA patients with newly diagnosed ALL administered by adult treatment teams, we performed a prospective study, CALGB 10403, with doses and schedule identical to those in the Children's...
Blood CLINICAL TRIALS AND OBSERVATIONS
Thu Apr 04, 2019 19:00
Celltrion Partners with the Canadian Biotech Company, iProgen Biotech to Develop a Series of Novel ADCs
INCHEON, South Korea & VANCOUVER, British Columbia--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/CD20?src=hash" target="_blank"gt;#CD20lt;/agt;--Celltrion and iProgen Biotech announced partnership for the development of novel ADCs against validated antibody targets, including HER2 and CD20.
Business Wire Health: Clinical Trials News
04:51
AVITA Medical Announces Presentation at ABA Meeting Highlighting Results of Study Using RECELL® System to Treat Third-Degree Burns in Pediatric Patients
VALENCIA, Calif. & MELBOURNE, Australia--(BUSINESS WIRE)--AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, announced that interim results describing clinical outcomes for pediatric patients treated using the RECELL® System were presented at the American Burn Association (ABA) 51st Annual Meeting in Las Vegas by Jeffrey Carter, MD, FACS University Medical Center New Orleans Burn Center and LSU Health New Orleans School of Medicine. Patients enrolled in the Investig
Business Wire Health: Clinical Trials News
03:00
Celgene recibe la opinión positiva del CHMP para las combinaciones de REVLIMID® (lenalidomida) e IMNOVID® (pomalidomida) en pacientes con mieloma múltiple
SUMMIT, Nueva Jersey--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG), ha anunciado que el Comité de Medicamentos de Uso Humano (CHMP) de la Agencia Europea de Medicamentos (EMA) ha adoptado opiniones positivas sobre dos regímenes triples basados en los medicamentos IMiD® patentados por Celgene: REVLIMID (lenalidomida) e IMNOVID (pomalidomida). En concreto, el CHMP ha recomendado la aprobación de una indicación ampliada de REVLIMID como terapia de combinación con bortezomib y dexametasona (
Business Wire Health: Clinical Trials News
Fri Apr 05, 2019 23:31
Celgene obtient des avis favorables du CHMP pour des associations triples de traitements à base de REVLIMID® et IMNOVID® pour les patients atteints de myélome multiple
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) a annoncé que le comité des médicaments à usage humain (CHMP) de l'Agence Européenne des Médicaments (EMA) a adopté des avis favorables pour deux triplettes à base de deux IMIDs® de Celgene : REVLIMID® (lénalidomide) et IMNOVID® (pomalidomide), dans le traitement du myélome multiple. Le CHMP a recommandé l'approbation d'une extension d'indication pour REVLIMID® en association avec le bortézomib et la dexaméthasone (RVd) pour le tr
Business Wire Health: Clinical Trials News
Fri Apr 05, 2019 23:23
Acceleron Announces Departure of Chief Medical Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced that Robert K. Zeldin, M.D., Chief Medical Officer, is no longer employed by the company, as of today. The company has begun an executive search for his replacement. "We thank Robert for his contributions to the Company over the last 9 months and wish him the best in his fut
Business Wire Health: Clinical Trials News
Fri Apr 05, 2019 23:01
Global Anorexia Nervosa Clinical Trials Review, H2, 2018 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Anorexia Nervosa Global Clinical Trials Review, H2, 2018" clinical trials has been added to ResearchAndMarkets.com's offering. Anorexia Nervosa Global Clinical Trials Review, H2, 2018 provides an overview of Anorexia Nervosa clinical trials scenario. This report provides top line data relating to the clinical trials on Anorexia Nervosa. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report
Business Wire Health: Clinical Trials News
Fri Apr 05, 2019 18:00
Global Amyotrophic Lateral Sclerosis Clinical Trials Review, H2, 2018 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Amyotrophic Lateral Sclerosis Global Clinical Trials Review, H2, 2018" clinical trials has been added to ResearchAndMarkets.com's offering. Amyotrophic Lateral Sclerosis Global Clinical Trials Review, H2, 2018" provides an overview of Amyotrophic Lateral Sclerosis clinical trials scenario. This report provides top line data relating to the clinical trials on Amyotrophic Lateral Sclerosis. Report includes an overview of trial numbers and their average enrollment in
Business Wire Health: Clinical Trials News
Fri Apr 05, 2019 17:50
Global Anterior Uveitis Clinical Trials Review, H2, 2018 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Anterior Uveitis Global Clinical Trials Review, H2, 2018" clinical trials has been added to ResearchAndMarkets.com's offering. Anterior Uveitis Global Clinical Trials Review, H2, 2018" provides an overview of Anterior Uveitis clinical trials scenario. This report provides top line data relating to the clinical trials on Anterior Uveitis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report
Business Wire Health: Clinical Trials News
Fri Apr 05, 2019 17:24
Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Biologics License Application to U.S. FDA
SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that Celgene has submitted a Biologics License Application (BLA) for luspatercept, an erythroid maturation agent, for the treatment of adult patients with very low to intermediate risk myelodysplastic syndromes (MDS)-associated anemia who have ring sideroblasts and require red blood cell (RBC) transfusions and for the treatment of adult patients with beta
Business Wire Health: Clinical Trials News
Fri Apr 05, 2019 16:28
UroGen Pharma Announces Presentation of Analysis from Phase 3 OLYMPUS Trial of UGN-101 for Patients with Low-Grade Upper Tract Urothelial Cancer
NEW YORK--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced a new presentation from the pivotal Phase 3 OLYMPUS trial of UGN-101 (mitomycin gel) for instillation, an investigational formulation for the primary non-surgical treatment of patients with low-grade upper tract urothelial cancer (LG UTUC). The analysis, which discusses the minimally invasive chemoablation approach
Business Wire Health: Clinical Trials News
Fri Apr 05, 2019 16:12
Gilead Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Once-Daily Descovy® for HIV Pre-Exposure Prophylaxis
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the company has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for Descovy® (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection among individuals who are HIV-negative and at risk for HIV. A Priority Review voucher was submitted with the filing, le
Business Wire Health: Clinical Trials News
Fri Apr 05, 2019 15:30
Ragweed Pollen Allergy Pipeline Review, H1 2019 Featuring ALK-Abello, Allergy Therapeutics, Anergis, Astellas Pharma, & Biomay - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Ragweed Pollen Allergy - Pipeline Review, H1 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. Ragweed Pollen Allergy - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Ragweed Pollen Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological
Business Wire Health: Clinical Trials News
Fri Apr 05, 2019 15:21
Ocular Hypertension Pipeline Review, H1 2019 by Stage of Development, Drug Target, MoA, RoA and Molecule Type - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Ocular Hypertension - Pipeline Review, H1 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. Ocular Hypertension - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Ocular Hypertension (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological actio
Business Wire Health: Clinical Trials News
Fri Apr 05, 2019 15:11
Becker Muscular Dystrophy - Pipeline Review, H1 2019 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Becker Muscular Dystrophy - Pipeline Review, H1 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. Becker Muscular Dystrophy - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Becker Muscular Dystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive
Business Wire Health: Clinical Trials News
Fri Apr 05, 2019 15:07
Gamida Cell to Present at the 18th Annual Needham Healthcare Conference
BOSTON--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24GMDA&src=ctag" target="_blank"gt;$GMDAlt;/agt;--Gamida Cell will present an overview of the company at the 18th Annual Needham Healthcare Conference on Tuesday, April 9, 2019.
Business Wire Health: Clinical Trials News
Fri Apr 05, 2019 15:01
LivaNova Reports Preliminary Unaudited First Quarter 2019 Revenue Results
LONDON--(BUSINESS WIRE)--lt;a href="https://twitter.com/search?q=%24LIVN&src=ctag" target="_blank"gt;$LIVNlt;/agt;--LivaNova today announced preliminary unaudited revenue results for the quarter ended March 31, 2019.
Business Wire Health: Clinical Trials News
Fri Apr 05, 2019 15:00
Syros Announces Pricing of $70 Million Concurrent Public Offerings
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that it has priced its concurrent underwritten public offerings of (i) 8,667,333 shares of its common stock and accompanying Class A warrants to purchase up to 1,951,844 shares of its common stock, at a combined price to the public of $7.50 per common share and accompanying Class A warrant and (ii) 666 shares of its Series A conv
Business Wire Health: Clinical Trials News
Fri Apr 05, 2019 14:15
Samenvatting: Roche presenteert gegevens van Biognosys voor het gebruik van de ontdekking van proteomics in klinische proeven
PALM SPRINGS, Californië & SCHLIEREN, Zwitserland--(BUSINESS WIRE)--Klinische onderzoekers kunnen binnenkort duizenden eiwitten uit patiëntweefsels direct meten en kwantificeren in klinische proeven met behulp van de volgende generatie labelvrije proteomics technologie ontwikkeld door Biognosys, een Zwitserse proteomics bedrijf. Dit werd voorgesteld door een presentatie van een gezamenlijke studie onder leiding van Dr. Axel Ducret (F. Hoffmann-La Roche Ltd) op de MSACL 2019 conferentie (Mass...
Business Wire Health: Clinical Trials News
Fri Apr 05, 2019 10:49
AVITA Medical RECELL® System Health Economic Data Project USD $28 Million in Annual Savings at a Single Major Burn Center Versus Standard of Care
VALENCIA, Calif. & MELBOURNE, Australia--(BUSINESS WIRE)--AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, announced health economic data projecting that use of the RECELL System to treat patients with severe burns could save a major U.S. burn center up to USD $28 million annually compared to treatment with the standard of care. The health economic results were presented at the American Burn Association (ABA) 51st Annual Meeting in Las Vegas by Kevin Foster, MD,...
Business Wire Health: Clinical Trials News
Fri Apr 05, 2019 02:19
Shionogi stellt neue Daten auf dem European Congress of Clinical Microbiology and Infectious Diseases 2019 vor
OSAKA, Japan, AMSTERDAM und FLORHAM PARK, New Jersey--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Hauptsitz: Osaka, Japan; President und CEO: Isao Teshirogi, Ph.D.), Shionogi B.V. und Shionogi Inc., das europäische und das US-amerikanische Tochterunternehmen von Shionogi & Co., Ltd, („Shionogi") kündigten heute zwölf Präsentationen im Rahmen des European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) an, der vom 13. bis 16. April 2019 in Amsterdam stattfindet. Acht Poster
Business Wire Health: Clinical Trials News
Fri Apr 05, 2019 01:27
Syros Announces Proposed Concurrent Public Offerings of Common Stock with Warrants to Purchase Common Stock and Preferred Stock with Warrants to Purchase Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced that it is offering to sell, subject to market and other conditions, (i) shares of its common stock and Class A warrants to purchase common stock, and (ii) shares of its Series A convertible preferred stock and Class A warrants to purchase common stock, in two concurrent but separate underwritten public offerings. The offerings a
Business Wire Health: Clinical Trials News
Thu Apr 04, 2019 23:18
Acceleron Discontinues Development of Phase 1 Molecule ACE-2494
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced it is discontinuing development of ACE-2494, a systemic muscle agent the company had been studying in a Phase 1 healthy volunteer trial for the potential treatment of neuromuscular disorders. "Although ACE-2494 showed promising early signs of target engagement in our r
Business Wire Health: Clinical Trials News
Thu Apr 04, 2019 23:05
Horizon Pharma plc Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN--(BUSINESS WIRE)--Horizon Pharma plc (Nasdaq: HZNP) today announced that the compensation committee of its board of directors approved the grant on April 1, 2019 of inducement restricted stock units for an aggregate of 48,477 ordinary shares to 14 new employees. The restricted stock units vest over three years, with 1/3 of the shares vesting on each anniversary of the applicable vesting commencement date. All awards are subject to the new employee's continued service relationship with th
Business Wire Health: Clinical Trials News
Thu Apr 04, 2019 23:05
Immunomic Therapeutics to Participate at World Vaccine Congress Washington 2019
ROCKVILLE, Md.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/allergies?src=hash" target="_blank"gt;#allergieslt;/agt;--Immunomic Therapeutics, Inc. announced today that it will participate at the World Vaccine Congress Washington being held in Washington, D.C.
Business Wire Health: Clinical Trials News
Thu Apr 04, 2019 23:05
4th World Congress on Interventional Therapies for Type 2 Diabetes Focuses on Barriers to Utilization of Bariatric/Metabolic Surgery and Hosts the First-Ever Joint Consensus Conference on Obesity & Diabetes Stigma
NEW YORK--(BUSINESS WIRE)--45 Leading Global Societies and 90 World-Renowned Experts to Gather in New York City at the 4th WCITD
Business Wire Health: Clinical Trials News
Thu Apr 04, 2019 22:40
Signifikante Steigerung der Überlebensraten bei kardiogenem Schock seit der FDA PMA-Zulassung von Impella vor drei Jahren
DANVERS, Massachusetts--(BUSINESS WIRE)--In dieser Woche vor drei Jahren erhielt Abiomed (NASDAQ: ABMD) für seine Impella-Herzpumpe die FDA PMA-Zulassung zur Behandlung von kardiogenem Schock bei AMI. Zum Zeitpunkt der FDA PMA-Zulassung von Impella betrug die Überlebensrate bis zur Explantation bei kardiogenem Schock laut der Impella Quality Assurance (IQ) Database in den Vereinigten Staaten 51 %.1 Heute tragen Impella-Herzpumpen in Kombination mit Best Practices, wie beispielsweise der Einsatz
Business Wire Health: Clinical Trials News
Thu Apr 04, 2019 22:21
U.S. FDA Approves IBRANCE® (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to expand the indications for IBRANCE® (palbociclib) in combination with an aromatase inhibitor or fulvestrant to include men with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. The approval is based on data from electronic health records and postmarketin
Business Wire Health: Clinical Trials News
Thu Apr 04, 2019 21:57
Shionogi présentera de nouvelles données au Congrès européen de microbiologie clinique et des maladies infectieuses 2019
OSAKA, Japon, AMSTERDAM, Pays-Bas et FLORHAM PARK, New Jersey--(BUSINESS WIRE)--Shionogi & Co, Ltd. (Siège social : Osaka, Japon ; Président et CEO : Isao Teshirogi, Ph.D.) et Shionogi B.V. et Shionogi Inc. les filiales européennes et américaines de Shionogi & Co, Ltd (ci-après "Shionogi") ont annoncé aujourd'hui 12 présentations de données qui auront lieu au Congrès européen de microbiologie clinique et maladies infectieuses (ECCMID), tenu du 13 au 16 avril 2019 à Amsterdam. Huit poste
Business Wire Health: Clinical Trials News
Thu Apr 04, 2019 21:37
Cook Biotech Announces Collaboration with Progressive Medical for Biodesign® Hernia Graft in US
WEST LAFAYETTE, Ind.--(BUSINESS WIRE)--Cook Biotech announced a new sales collaboration with Progressive Medical. Sales representatives employed by Progressive Medical will manage and support sales in the field for the Cook Biotech Biodesign Hernia Graft. Progressive Medical has sold and distributed products focused on overall cost effectiveness, efficiency, improved patient outcomes, and safety for over 33 years. "It is our mission and commitment to support improved outcomes, quality of care,
Business Wire Health: Clinical Trials News
Thu Apr 04, 2019 21:24
Riassunto: Shionogi presenterà nuovi dati al Congresso Europeo di microbiologia clinica e malattie infettive 2019
OSAKA, Giappone, AMSTERDAM e FLORHAM PARK, N.J.--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Sede centrale: Osaka, Giappone; Presidente e CEO: Isao Teshirogi, Ph.D.) e Shionogi B.V. e Shionogi Inc., rispettivamente le affiliate europea e statunitense di Shionogi & Co., Ltd, (d'ora in avanti "Shionogi") oggi hanno annunciato 12 presentazioni di dati nell'ambito dell'European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), che si svolgerà ad Amsterdam dal 13 al 16 aprile 20
Business Wire Health: Clinical Trials News
Thu Apr 04, 2019 20:11
2019 Study on Clinical Trial Packaging - Global Market Analysis, Trends and Forecast 2015-2027 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Global Clinical Trial Packaging Market Analysis & Trends - Industry Forecast to 2027" report has been added to ResearchAndMarkets.com's offering. The Global Clinical Trial Packaging Market is poised to grow strong during the forecast period 2017 to 2027. Some of the prominent trends that the market is witnessing include rising importance of booklet labels, increasing emphasis on the research and development and advancements in mobile technologies. This industry
Business Wire Health: Clinical Trials News
Thu Apr 04, 2019 19:16
HepQuant's Disease Severity Index (DSI) Demonstrates Hepatic Functional Improvement in High Percentage of NASH Patients Treated with Obeticholic Acid: Results from INTERCEPT 747-117
DENVER--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/NASH?src=hash" target="_blank"gt;#NASHlt;/agt;--HepQuant, LLC, a Greenwood Village, Colo.-based company with a unique, patented and patent-pending blood-based technology for evaluating the function of the liver, today announced the results from its proprietary HepQuant SHUNT™ Liver Diagnostic Kit in INTERCEPT's placebo-controlled clinical trial of obeticholic acid (OCA), 747-117. The HepQuant DSI results from the trial will be presented...
Business Wire Health: Clinical Trials News
Thu Apr 04, 2019 19:00
Merz présentera de nouvelles données cliniques dans le domaine de l'esthétique au congrès AMWC 2019
FRANCFORT, Allemagne--(BUSINESS WIRE)--Merz, leader mondial de l'esthétique et des neurotoxines, a annoncé aujourd'hui que des données cliniques sur l'utilisation du portefeuille de Merz Aesthetics (Belotero®, Cellfina®, Radiesse®, Ultherapy® et la toxine botulique), feront l'objet de présentations orales et par affiches à l'occasion de l'édition 2019 du Congrès mondial de la médecine esthétique et anti-âge (AMWC), qui se tiendra du jeudi 4 au samedi 6 avril 2019 à Monte-Carlo (Monaco). En plus
Business Wire Health: Clinical Trials News
Thu Apr 04, 2019 18:54
Riassunto: Merz presenta ad AMWC 2019 nuovi dati clinici in materia di medicina estetica
FRANCOFORTE, Germania--(BUSINESS WIRE)--Merz, leader globale nella medicina estetica e nelle neurotossine, ha oggi annunciato che illustrerà dati clinici sull'utilizzo del portafoglio di Merz Aesthetics, inclusi Belotero®, Cellfina®, Radiesse®, Ultherapy® e la tossina botulinica, nel corso di presentazioni orali e poster al 2019 Aesthetic & Anti-Aging Medicine World Congress (AMWC), che si svolgerà da giovedì 4 aprile a sabato 6 aprile 2019 a Monte Carlo, nel Principato di Monaco. Oltre all
Business Wire Health: Clinical Trials News
Thu Apr 04, 2019 18:54
VenatoRx Pharmaceuticals Names Lisa Wittmer, Ph.D. Chief Development Officer
MALVERN, Pa.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/antibiotics?src=hash" target="_blank"gt;#antibioticslt;/agt;--Dr. Lisa Wittmer has 20+ years experience in global regulatory affairs along with developing, licensing and commercializing new therapeutics.
Business Wire Health: Clinical Trials News
Thu Apr 04, 2019 18:00
Resumen: Roche presenta datos de Biognosys para el uso de la proteómica de descubrimiento en los ensayos clínicos
PALM SPRINGS, Calif. & SCHLIEREN, Suiza--(BUSINESS WIRE)--Los investigadores clínicos podrán ser capaces de medir y cuantificar directamente miles de proteínas de los tejidos de los pacientes en los ensayos clínicos utilizando tecnología proteómica de próxima generación libre de etiquetas desarrollada por Biognosys, una empresa de proteómica Suiza. El comunicado en el idioma original, es la versión oficial y autorizada del mismo. La traducción es solamente un medio de ayuda y deberá ser compara
Business Wire Health: Clinical Trials News
Thu Apr 04, 2019 17:55
Physicians Protocol Joins the AcuFocus IC-8® Lens Clinical Study for Patients with Cataracts
GREENSBORO, N.C.--(BUSINESS WIRE)--Karl Stonecipher, MD at Physicians Protocol, is participating in the AcuFocus clinical study for the IC-8 intraocular lens designed for cataracts.
Business Wire Health: Clinical Trials News
Thu Apr 04, 2019 16:05
Shionogi to Present New Data at European Congress of Clinical Microbiology and Infectious Diseases 2019
OSAKA, Japan & AMSTERDAM, Netherlands & FLORHAM PARK, N.J.--(BUSINESS WIRE)--Shionogi announced 12 data presentations taking place at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).
Business Wire Health: Clinical Trials News
Thu Apr 04, 2019 16:00
Global Alpha-Mannosidosis Clinical Trials Review, H2 2018 Report Featuring Chiesi Farmaceutici, Zymenex, Larix, Nuo Therapeutics, Fate Therapeutics & Cromsource - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Alpha-Mannosidosis Global Clinical Trials Review, H2, 2018" clinical trials has been added to ResearchAndMarkets.com's offering. "Alpha-Mannosidosis Global Clinical Trials Review, H2, 2018" provides an overview of Alpha-Mannosidosis clinical trials scenario. This report provides top line data relating to the clinical trials on Alpha-Mannosidosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. T
Business Wire Health: Clinical Trials News
Thu Apr 04, 2019 15:54
Samenvatting: Merz presenteert nieuwe esthetische klinische gegevens op AMWC 2019
FRANKFURT, Duitsland--(BUSINESS WIRE)--Merz, een wereldleider in esthetica en neurotoxinen, heeft vandaag aangekondigd dat klinische gegevens over het gebruik van de Merz Aesthetics portfolio, waaronder Belotero®, Cellfina®, Radiesse®, Ultherapy® en Botulinum Toxin te zien zijn in mondelinge en poster presentaties op het Aesthetic & Anti-Aging Medicine World Congress (AMWC) 2019, dat wordt gehouden van donderdag 4 april tot zaterdag 6 april 2019 in Monte-Carlo, Monaco. Naast de onderstaande
Business Wire Health: Clinical Trials News
Thu Apr 04, 2019 15:44
Resumen: Merz presentará nuevos datos clínicos de medicina estética en el AMWC 2019
FRÁNCFORT, Alemania--(BUSINESS WIRE)--Merz, líder mundial en medicina estética y neurotoxinas, ha anunciado hoy que los datos clínicos sobre el uso de la cartera de productos de medicina estética de Merz, que incluye Belotero®, Cellfina®, Radiesse®, Ultherapy® y la toxina botulínica, se darán a conocer en distintas presentaciones orales y pósters en el congreso mundial de medicina estética y antienvejecimiento (Aesthetic & Anti-Aging Medicine World Congress, AMWC) de 2019, que se tendrá lug
Business Wire Health: Clinical Trials News
Thu Apr 04, 2019 15:33
Puma Biotechnology Expands Cohorts in Phase II SUMMIT Trial of Neratinib in Cancer Patients with Tumors with Activating EGFR or HER2 Mutations
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology expanded two more cohorts from the P II SUMMIT trial investigating neratinib in patients with activating EGFR or HER2 mutations.
Business Wire Health: Clinical Trials News
Thu Apr 04, 2019 15:30
Samenvatting: Shionogi presenteert nieuwe gegevens op het European Congress of Clinical Microbiology and Infectious Diseases 2019
OSAKA, Japan, AMSTERDAM, & FLORHAM PARK, N.J.--(BUSINESS WIRE)--Shionogi & Co. (hoofdkantoor: Osaka, Japan; President en CEO: Isao Teshirogi, Ph.D.) en Shionogi B.V. en Shionogi Inc., de Europese en Amerikaanse dochterondernemingen van respectievelijk Shionogi & Co., Ltd. (hierna "Shionogi") hebben vandaag 12 presentaties aangekondigd die plaatsvinden op het European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), dat op 13-16 april 2019 in Amsterdam plaatsvindt. Ach
Business Wire Health: Clinical Trials News
Thu Apr 04, 2019 15:28
Resumen: Shionogi presentará nuevos datos en el Congreso Europeo de Microbiología Clínica y Enfermedades Infecciosas 2019
OSAKA, Japón, ÁMSTERDAM y FLORHAM PARK, Nueva Jersey--(BUSINESS WIRE)--Shionogi & Co., Ltd. (sede: Osaka, Japón; presidente y CEO: Isao Teshirogi, Ph.D.) y Shionogi BV y Shionogi Inc., filiales europea y estadounidense de Shionogi & Co., Ltd respectivamente, (en adelante, "Shionogi") han anunciado hoy 12 presentaciones de datos que se llevarán a cabo en el Congreso Europeo de Microbiología Clínica y Enfermedades Infecciosas (European Congress of Clinical Microbiology and Infectious Dise
Business Wire Health: Clinical Trials News
Thu Apr 04, 2019 15:25
Cardiogenic Shock Survival Rates Improve Significantly in Three Years Since Impella FDA PMA Approval
DANVERS, Mass.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/heartrecovery?src=hash" target="_blank"gt;#heartrecoverylt;/agt;--Cardiogenic Shock Survival Rates Improve Significantly in Three Years Since Impella FDA PMA Approval
Business Wire Health: Clinical Trials News
Thu Apr 04, 2019 15:11
Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2019 Financial Results on April 25, 2019
BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its first quarter 2019 financial results on Thursday, April 25, 2019 after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows: LIVE access on Thursday, April 25, 2019 1:30 p.m. Pacific Time / 4:30 p.m. Eastern T
Business Wire Health: Clinical Trials News
Thu Apr 04, 2019 15:00
Roche Presents Data from Biognosys for Use of Discovery Proteomics in Clinical Trials
PALM SPRINGS, Calif. & SCHLIEREN, Switzerland--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/MSACL?src=hash" target="_blank"gt;#MSACLlt;/agt;--Roche suggests that discovery proteomics might soon move into the clinical trial setting, in a recent mock study using Biognosys' data.
Business Wire Health: Clinical Trials News
Fri Apr 05, 2019 11:01
Cortexyme Elects Christopher J. Senner to Its Board of Directors
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc., a privately held, clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer's disease (AD) and other degenerative diseases, today announced the election of veteran biopharma finance executive Christopher J. Senner to the company's Board of Directors. "Chris Senner's deep financial expertise, gained at some of our industry's most notable companies,
Business Wire Health: Clinical Trials News
Thu Apr 04, 2019 15:00
AtriCure to Announce First Quarter 2019 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2019 financial results on Thursday, April 25, 2019. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, April 25, 2019 to discuss its first quarter 2019 financial results. The call may be accessed through an operator by calling (844) 884-9951 for dom
Business Wire Health: Clinical Trials News
Thu Apr 04, 2019 15:00
IMV Inc. to Present at the Bloom Burton & Co. Healthcare Investor Conference; Announces Update to Presentation at H.C. Wainwright Investor Conference
DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company today announced that IMV Chief Executive Officer, Frederic Ors will be making an investor presentation at the 2019 Bloom Burton & Co Healthcare Investor Conference, which will be held from April 30 to May 1, 2019 in Toronto, Ontario. IMV's presentation details include: Date: Wednesday, May 1, 2019 Time: 11:00 a.m. ET Location: Metro Toronto Convention Centre, 255 Front St W, T
Business Wire Health: Clinical Trials News
Thu Apr 04, 2019 14:05
Full Two-Year Data from Orthofix M6-C Artificial Cervical Disc Study Shows Significant Improvement in Pain, Function and Quality of Life Scores
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company focused on musculoskeletal products and therapies, today announced the full two-year outcomes from its U.S. Investigational Device Exemption (IDE) study of the M6-C™ artificial cervical disc. Dr. Jack Zigler, orthopedic spine surgeon at Texas Back Institute and an investigator in the study, presented the study results during the International Society for the Advancement of Spine Surgery (ISA
Business Wire Health: Clinical Trials News
Thu Apr 04, 2019 14:00
Loop Medical Receives up to USD 3.2 Million to Finalize the Development and Validation of a Breakthrough Painless and Easy-to-Use Blood Collection Device
LAUSANNE, Switzerland--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/bloodtests?src=hash" target="_blank"gt;#bloodtestslt;/agt;--Loop Medical gets second grant from Bill and Melinda Gates Foundation to support pre-production and clinical trials of novel blood collection device.
Business Wire Health: Clinical Trials News
Thu Apr 04, 2019 14:00
Innovus Pharma Receives Expanded Claims for Its UriVarx® Product in Canada to Include Symptoms of Urinary Incontinence
SAN DIEGO--(BUSINESS WIRE)--Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the "Company") (OTCQB Venture Market: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men's and women's health and respiratory diseases, today announced that its marketed product UriVarx® has received approval for an expanded claim to include "helps improve the symptoms of urinary incontinence." Inn
Business Wire Health: Clinical Trials News
Thu Apr 04, 2019 13:00
Shionogi présentera des données cliniques sur le Lusutrombopag lors du International Liver Congress™ 2019 de l'Association Européenne pour l'Étude du Foie (EASL)
OSAKA, Japon et AMSTERDAM, Pays-Bas--(BUSINESS WIRE)--Shionogi & Co, Ltd. et sa filiale européenne, Shionogi B.V. (ci-après "Shionogi"), a annoncé qu'elle présentera quatre posters sur le Lusutrombopag, un agoniste des récepteurs de la thrombopoïétine (TPO) à petites molécules à administration orale unique quotidienne, lors du International Liver Congress™, la réunion annuelle de l'Association Européenne pour l'Étude du Foie (EASL), qui se tiendra à Vienne, Autriche du 10 au 14 avril 2019.
Business Wire Health: Clinical Trials News
Thu Apr 04, 2019 12:58
Samenvatting: Shionogi presenteert klinische gegevens over Lusutrombopag op het International Liver Congress™ 2019 van de European Association for the Study of the Liver (EASL)
OSAKA, Japan & AMSTERDAM, NL--(BUSINESS WIRE)--Shionogi & Co., Ltd. en haar Europese dochteronderneming, Shionogi B.V. (hierna "Shionogi"), kondigde aan dat het vier posters zal presenteren op lusutrombopag, een eenmaal daags, mondeling toegediende, kleine moleculaire trombopoïetine (TPO) receptor agonist, op het International Liver Congress™, de jaarlijkse bijeenkomst van de European Association for the Study of the Liver (EASL), die zal worden gehouden in Wenen, Oostenrijk, 10-14 april...
Business Wire Health: Clinical Trials News
Thu Apr 04, 2019 12:50
Resumen: Shionogi presentará datos clínicos sobre lusutrombopag en el International Liver Congress™ 2019 de la Asociación Europea para el Estudio del Hígado (EASL)
OSAKA, Japón y ÁMSTERDAM, Países Bajos--(BUSINESS WIRE)--Shionogi & Co., Ltd. y su filial europea, Shionogi BV (en adelante, "Shionogi"), han anunciado que presentarán cuatro pósters sobre lusutrombopag, un agonista del receptor de trombopoyetina (TPO) de molécula pequeña administrado por vía oral una vez al día, en el International Liver Congress™, el congreso anual de la Asociación Europea para el Estudio del Hígado (EASL, European Association for the Study of the Liver), que se celebrará
Business Wire Health: Clinical Trials News
Thu Apr 04, 2019 12:43
Merz stellt neue klinische Daten zum Ästhetik-Portfolio auf dem AMWC Weltkongress 2019 vor
FRANKFURT, Deutschland--(BUSINESS WIRE)--Merz, einer der weltweit führenden Anbieter im Bereich Ästhetik und Neurotoxine, gab heute bekannt, dass das Unternehmen auf dem Aesthetic & Anti-Aging Medicine World Congress (AMWC) die neuesten klinischen Daten zur Verwendung des Portfolios von Merz Aesthetics präsentieren wird. Die Daten zum Portfolio, das die Produkte Belotero®, Cellfina®, Radiesse®, Ultherapy® und Botulinum Toxin umfasst, werden vom 04. April bis 6.April 2019 in Monte-Carlo, Mon
Business Wire Health: Clinical Trials News
Thu Apr 04, 2019 11:20
Merz to Present New Aesthetics Clinical Data at AMWC 2019
FRANKFURT, Germany--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/AMWC2019?src=hash" target="_blank"gt;#AMWC2019lt;/agt;--Merz, a global leader in aesthetics and neurotoxins, announced today that clinical data on the use of the Merz Aesthetics portfolio, including Belotero®, Cellfina®, Radiesse®, Ultherapy® and Botulinum Toxin will be featured in oral and poster presentations at the 2019 Aesthetic & Anti-Aging Medicine World Congress (AMWC), to be held from Thursday, April 4 to Saturday,...
Business Wire Health: Clinical Trials News
Thu Apr 04, 2019 11:19
Overweight Obesity - Midlothian VA
Click image to enlarge The SELECT Study is being done to see if semaglutide can reduce the risk of cardiovascular events such as heart attack or stroke. Previous studies of semaglutide have shown that using semaglutide reduced the risk of cardiovascular events in some people with type 2 diabetes. Semaglutide is already approved in some countries at a lower dose, to treat type 2 diabetes. The SELECT study will examine the effect of semaglutide in people with established cardiovascular disease and...
ClinicalConnection.com New Clinical Trials
Fri Apr 05, 2019 00:00
ADHD (Attention Deficit Hyperactivity Disorder) - Midlothian VA
Click image to enlargeCentanafadine is a non-stimulant, triple reuptake inhibitor that modulates norepinephrine, dopamine and serotonin reuptake with the intent of improving focus, attention, and specific higher level cognitive skills in patients with ADHD. Two phase II clinical trials in adults, including a phase IIb trial, have been completed for centanafadine, setting the stage for the start of phase III trials in ADHD. It can take up to 28 days for your study doctor to confirm you are eligible...
ClinicalConnection.com New Clinical Trials
Fri Apr 05, 2019 00:00
Acne Study - San Diego CA
Do you have acne? You may be a candidate for our clinical research study!We are currently enrolling qualified participants in a clinical research study for an investigational topical cream.If you are interested in participating in our Acne study, please fill out the form below.
ClinicalConnection.com New Clinical Trials
Fri Apr 05, 2019 00:00
Actinic Keratosis - Sherman Oaks CA
it is a Actinic keratosis. Participants Must have minimum of 5 to 10 Ak lisions.
ClinicalConnection.com New Clinical Trials
Thu Apr 04, 2019 00:00
<b>Osteoarthritis - Multiple Locations in South Africa</b>
Trouble getting around because of hip or knee pain? Do you suffer from hip or knee pain, stiffness and swelling related to arthritis? Paid research studies in your area are now enrolling. Research studies are an important part of developing potential future treatment options. Without them, progress in medicine would not be possible. Right now, doctors are looking for people with hip or knee pain from arthritis to volunteer for local research studies. * In a clinical research study, the participants...
ClinicalConnection.com New Clinical Trials
Thu Apr 04, 2019 00:00
<b>Ulcerative Colitis - Multiple Locations in South Africa</b>
Research study needs volunteers with ulcerative colitis A clinical research study is enrolling people with ulcerative colitis who have tried medication but still have moderate to severe symptoms. Volunteer for this study and you may receive: Compensation Study-related medical care * In a clinical research study, the participants may receive investigational study product or may receive an inactive substance, or placebo, depending on the study design. Participants receive study-related care from...
ClinicalConnection.com New Clinical Trials
Thu Apr 04, 2019 00:00
<b>Heart Disease - Multiple Locations in South Africa</b>
Have heart disease? Do you or a loved one have heart disease with high cholesterol? If so, you may qualify for local research studies testing a study medication not available from your regular doctor. Research studies are an important part of developing potential future treatment options. Without them, progress in medicine would not be possible. Right now, doctors are looking for people with heart disease to volunteer for local heart health research studies. * In a clinical research study, the...
ClinicalConnection.com New Clinical Trials
Thu Apr 04, 2019 00:00
<b>Eczema - Multiple Locations in Canada</b>
Research study needs people with atopic dermatitis Have you or a loved one been living with atopic dermatitis (a chronic, recurring, inflammatory, and itchy skin condition) for 2 years or more? If so, you (or they) may qualify for a clinical research study, which is currently testing an investigational topical cream for atopic dermatitis. Those who qualify and participate in this study may receive: Study-related care from local doctors Investigational study medication Participants must be 18...
ClinicalConnection.com New Clinical Trials
Thu Apr 04, 2019 00:00
<b>Endometriosis - Multiple Locations in South Africa</b>
Do you or a loved one have Endometriosis? Does Endometriosis prevent you from living life to its fullest? If so, you may qualify for local research studies. Right now, local doctors are looking for women with Endometriosis to join local research studies. Research studies are an important part of developing potential future treatment options. Without them, progress in medicine would not be possible. Right now, doctors are looking for women with Endometriosis to volunteer for local research...
ClinicalConnection.com New Clinical Trials
Thu Apr 04, 2019 00:00
Imbrium Therapeutics Announces FDA Orphan Drug Designation for Tinostamustine for The Treatment of T-Cell Prolymphocytic Leukemia
STAMFORD, Conn. – March 28, 2019 – Imbrium Therapeutics L.P., a clinical-stage biopharmaceutical company and operating subsidiary of Purdue Pharma L.P., in conjunction with Mundipharma EDO GmbH, today announced that the U.S. Food and...
Drugs.com - Clinical Trials
Thu Mar 28, 2019 08:04
Immunocore's Lead Asset Tebentafusp Gains Fast Track Designation for Metastatic Uveal Melanoma
OXFORD, England & CONSHOHOCKEN, Pa.--April 03, 2019 --Immunocore Limited, a leading T Cell Receptor (TCR) biotechnology company, today announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its...
Drugs.com - Clinical Trials
Thu Apr 04, 2019 08:04
Three pharma firms agree to pay $122.6m to settle kickback allegations
The US Department of Justice (DOJ) alleged that the three pharmaceutical firms have violated the False Claims Act by illegally paying the Medicare or Civilian Health and Medical The post Three pharma firms agree to pay $122.6m to settle kickback allegations appeared first on Pharmaceutical Business review.
PBR - Clinical Trials News
Fri Apr 05, 2019 12:11
Puma Biotechnology expands cohorts in phase II SUMMIT trial of Neratinib
The cohorts that have been expanded are (i) HER2 mutant patients with metastatic salivary gland cancer and (ii) patients with EGFR exon 18 mutation-positive lung cancer. The Phase The post Puma Biotechnology expands cohorts in phase II SUMMIT trial of Neratinib appeared first on Pharmaceutical Business review.
PBR - Clinical Trials News
Fri Apr 05, 2019 12:11
Twist Bioscience and LakePharma form strategic collaboration to provide antibody discovery and development services
Under the terms of the agreement, LakePharma will have the ability to offer Twist's proprietary antibody discovery and optimization platforms to their existing and future biopharmaceutical customers as The post Twist Bioscience and LakePharma form strategic collaboration to provide antibody discovery and development services appeared first on Pharmaceutical Business review.
PBR - Clinical Trials News
Fri Apr 05, 2019 12:11
Pfizer gets EC approval for Vizimpro lung cancer monotherapy
The approval was based on data from Archer 1050 randomized, multicenter, multinational and open-label phase 3 study conducted in patients with unresectable, metastatic or recurrent NSCLC harboring EGFR The post Pfizer gets EC approval for Vizimpro lung cancer monotherapy appeared first on Pharmaceutical Business review.
PBR - Clinical Trials News
Thu Apr 04, 2019 15:41
Sandoz resubmits biosimilar pegfilgrastim application to US FDA
Pegfilgrastim is a long-acting version of filgrastim and may be prescribed to appropriate cancer patients undergoing chemotherapy to enhance the production of infection-fighting white blood cells2. Studies have The post Sandoz resubmits biosimilar pegfilgrastim application to US FDA appeared first on Pharmaceutical Business review.
PBR - Clinical Trials News
Thu Apr 04, 2019 11:34
ViiV Healthcare announces Juluca (dolutegravir/rilpivirine) maintains HIV viral suppression at 148-weeks
These results were presented at the 25th Annual Conference of the British HIV Association (BHIVA) taking place from 2-5 April in Bournemouth, UK. Professor Chloe Orkin, Consultant Physician The post ViiV Healthcare announces Juluca (dolutegravir/rilpivirine) maintains HIV viral suppression at 148-weeks appeared first on Pharmaceutical Business review.
PBR - Clinical Trials News
Thu Apr 04, 2019 11:34
Corrigendum to "Design of VA Cooperative Study #591: CERV-PTSD, Comparative Effectiveness Research in Veterans with PTSD" [Contemp. Clin. Trials 41 (2015) 75–84]
Publication date: Available online 5 April 2019Source: Contemporary Clinical TrialsAuthor(s): Paula P. Schnurr, Kathleen M. Chard, Josef I. Ruzek, Bruce K. Chow, Mei-Chiung Shih, Patricia A. Resick, Edna B. Foa, Brian P. Marx, Grant D. Huang, Ying Lu
ScienceDirect Publication: Contemporary Clinical Trials
Sat Apr 06, 2019 16:35
Social incentives to encourage physical activity and understand predictors (STEP UP): Design and rationale of a randomized trial among overweight and obese adults across the United States
Publication date: Available online 4 April 2019Source: Contemporary Clinical TrialsAuthor(s): Joseph D. Harrison, Jeremy M. Jones, Dylan S. Small, Charles A.L. Rareshide, Gregory Szwartz, David Steier, James Guszcza, Pameljit Kalra, Brian Torio, Gregory Reh, Victoria Hilbert, Mitesh S. PatelAbstractBackgroundLess than half of adults in the United States (US) obtain the recommended level of physical activity. Social incentives, the influences that impact individuals to adjust their behaviors based...
ScienceDirect Publication: Contemporary Clinical Trials
Fri Apr 05, 2019 14:33

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου